A 54-year-old male on desvenlafaxine 100 mg daily for four years experiences depressive relapses every 2–3 months with lack of motivation, anhedonia, and preference for lying in bed, without any features suggestive of bipolar disorder. What is the most appropriate antidepressant to add to his current desvenlafaxine regimen?

Add Bupropion to Desvenlafaxine

For this 54-year-old male experiencing recurrent depressive episodes every 2-3 months despite 4 years on desvenlafaxine 100mg, the most appropriate antidepressant to add is bupropion. This recommendation prioritizes his specific symptom profile of amotivation, anhedonia, and lack of energy—symptoms that respond particularly well to dopaminergic augmentation.

Clinical Reasoning

Why Bupropion is the Optimal Choice

This patient's presentation is characterized by:

• Lack of motivation (amotivation)
• Disinterest in activities (anhedonia)
• Preference for lying in bed (anergia/psychomotor retardation)
• Avoidance of work and social interaction

These symptoms cluster around the reward-motivation-energy domain, which is mediated primarily by dopaminergic and noradrenergic pathways. Desvenlafaxine, as an SNRI, provides serotonergic and noradrenergic reuptake inhibition but lacks dopaminergic activity 1. Bupropion uniquely inhibits dopamine and norepinephrine reuptake without serotonergic effects, making it mechanistically complementary 2, 3.

Evidence-Based Support

The American College of Physicians guidelines emphasize that when patients fail to respond adequately to initial antidepressant therapy within 6-8 weeks, treatment modification is warranted 3. While the guidelines note "insufficient evidence exists to prefer one agent over another as second-line therapy," they specifically highlight that bupropion is "activating" and may produce "rapid improvement of energy level" 2. This activation profile directly addresses this patient's core symptoms.

Importantly, bupropion has a significantly lower rate of sexual adverse events compared to SSRIs and SNRIs 3, which is relevant for long-term tolerability in a middle-aged male already on an SNRI that may contribute to sexual dysfunction.

Practical Implementation

Starting regimen:

• Begin bupropion at 37.5 mg every morning
• Increase by 37.5 mg every 3 days as tolerated
• Target dose: 150 mg twice daily (maximum 300 mg/day total)
• Give the second dose before 3 PM to minimize insomnia risk 2

Continue desvenlafaxine 100 mg daily while adding bupropion—this combination therapy approach is supported by the recognition that multiple pharmacologic therapies may be required for patients not responding to first-line treatment 3.

Critical Monitoring Points

What to Watch For

1. Seizure risk: Bupropion carries a dose-dependent seizure risk 3. This patient has no mentioned seizure history, but avoid if any seizure disorder exists.

2. Activation symptoms: Monitor for agitation, anxiety, or insomnia, particularly in the first 1-2 weeks 3. These symptoms may indicate emerging behavioral activation requiring dose adjustment.

3. Blood pressure: Both desvenlafaxine and bupropion can increase blood pressure 1. Check BP at baseline and monitor regularly, especially given his age (54 years).

4. Response timeline: Expect improvement in energy and motivation within 2-4 weeks if bupropion is effective 2. Reassess at 6-8 weeks for full response 3.

Alternative Considerations (and Why They're Second-Line)

Mirtazapine would be an alternative if the patient had prominent insomnia and poor appetite, as it promotes sleep and weight gain 2, 3. However, this patient's primary issue is daytime amotivation and anhedonia, not sleep or appetite—making mirtazapine's sedating profile less ideal.

Switching to a different SNRI (like venlafaxine or duloxetine) is not recommended because he's already on an SNRI (desvenlafaxine) at an adequate dose for 4 years 1. The recurrent relapses suggest the serotonergic-noradrenergic mechanism alone is insufficient.

Lithium augmentation could be considered if this were truly treatment-resistant depression, but the guidelines suggest lithium primarily for "anticycling" in bipolar spectrum illness 2, which has been ruled out in this patient.

Common Pitfalls to Avoid

1. Don't assume this is "breakthrough depression" requiring a dose increase of desvenlafaxine. He's been on 100mg for 4 years—the issue is likely mechanistic insufficiency, not inadequate dosing. The FDA label shows 50mg is the recommended dose, with no clear benefit from higher doses 1.

2. Don't discontinue desvenlafaxine abruptly if considering a switch. SNRIs require slow taper to avoid discontinuation syndrome 4, 1.

3. Don't overlook the recurrent pattern. This patient relapses every 2-3 months despite continuous treatment, suggesting either inadequate continuation therapy or a symptom dimension (anhedonia/amotivation) not addressed by his current regimen 5, 6, 7.

4. Don't forget psychotherapy. While pharmacologic augmentation is the focus here, the guidelines emphasize that combined treatment with psychotherapy may improve outcomes, particularly for recurrent depression 3, 8. Consider referral for cognitive behavioral therapy or interpersonal therapy alongside medication adjustment.